New drug GenSci098 enters first human trial for thyroid eye disease

NCT ID NCT06569758

Recruiting now Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called GenSci098 in 76 adults with active thyroid eye disease (TED). The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo as a shot under the skin, and researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenSci098
What this could lead to: If successful, this could lead to a new treatment option for thyroid eye disease, potentially reducing symptoms like eye bulging and discomfort.
What could go wrong: This is a very early Phase 1 trial focused on safety, not yet on effectiveness. The drug may not work as hoped, and side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENSCI098 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENSCI098 SAFETY THYROID EYE DISEASE, TED TOLERABILITY

Contacts and locations

Locations

Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medication
RECRUITING

Shanghai, Shanghai Municipality, 200011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.